Anthony Sebba, MD
Rheumatology · Palm Harbor, FLNPI 1629077243
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $428,544 of the $587,644 with a category attached, or 72.9%. 18 manufacturers reported payments, led by Lilly USA, LLC at 34.8% of the total. Reporting peaked in 2019 at $263,229 and has fallen 96.4% since, to $9,491 in 2025. Among rheumatology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 736 payments — averaging $798.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$204K
- Sanofi$158K
- Genentech USA, Inc.$54K
- Sanofi-aventis U.S. LLC$52K
- Eli Lilly$33K
- Amgen$26K
- plus $59K from 12 others
Across 17 payments — averaging $1149.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$5K
- Eli Lilly$5K
- Sanofi US Services Inc.$3K
- AbbVie$3K
- Sanofi$2K
- F. Hoffmann-la Roche AG$2K
- plus $398 from 1 others
What the payments were for
- Consulting fees$78,25513%
- Speaking & faculty fees$428,54473%
- Travel & lodging$71,42512%
- Food & beverage$9,2922%
- Education$1290%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 282 | $204,302 |
| Sanofi | 164 | $157,730 |
| Genentech USA, Inc. | 53 | $54,483 |
| Sanofi-aventis U.S. LLC | 11 | $52,090 |
| Eli Lilly | 58 | $33,445 |
| Amgen | 55 | $26,207 |
| Gilead | 24 | $19,742 |
| Regeneron Healthcare Solutions, Inc. | 30 | $17,810 |
| Radius Health, Inc. | 13 | $11,371 |
| UCB, Inc. | 13 | $7,941 |
| Fresenius Kabi USA, LLC | 1 | $1,875 |
| AbbVie | 15 | $358 |
| Novartis | 1 | $100 |
| Pfizer | 10 | $70 |
| Johnson & Johnson | 2 | $47 |
| E.r. Squibb & Sons, L.L.C. | 2 | $40 |
| Mallinckrodt Enterprises LLC | 1 | $22 |
| Medexus Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$587,644 in reported general payments places this provider in the 95th percentile of 453 rheumatology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other rheumatology in Palm Harbor
- Alvin WellsDestin$2.4M
- Guillermo ValenzuelaPlantation$1.5M
- Julio Gonzalez-PaoliTampa$1.4M
- Ernesto RodriguezZephyrhills$958K
- Vinicius Costa Diniz DominguesDaytona Beach$921K
- Jonathan GreerBoynton Beach$757K
- Jigar ShahMargate$750K
- Rachel TateHollywood$729K
- Howard BuschLoxahatchee$717K
- Michael WeitzMiami$658K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.